drugset / Trial / NCT03280667
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
Phase 2
Unknown
59 enrolled
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Amgen · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC).
Timeline
- Start
- 2017-12-12
- Primary completion
- 2023-06-04
- Completion
- 2023-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |